English
Specials
    Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsOrchidpharma

    At Moneycontrol, the Results page helps you effectively track corporate announcements and results for various listed companies across both India and abroad. With our Results page, you can keep abreast with an updated, comprehensive view of all the profit/loss statements, company spendings, AGM outcomes, and quarterly and annual results from all these listed companies. Additionally, Moneycontrol also regularly tracks international MNCs listed on NASDAQ and Asian bourses, including popular companies like Apple, Google, Alibaba. Apart from finding solid copies of company results, stock movements consequent to these company results, expectations, and analytical post results copies, you will also find copies and articles detailing the earnings, impact, and all major announcements made to media/exchanges by these companies, so that you do not miss anything. We also provide you with concrete data points to help you spot profitable trades, stock build-ups, and bulk deals. At Moneycontrol, we also cover analysts/investors meetings; scrutinise results and data and BSE/NSE reports or news. The copies are not just full of information and data, but are also adequately supplemented with expert views, investor opinions, extensive interviews, videos, and a huge variety of explainers, analyses, and informative slideshows to help you gauge the market and make investment decisions in the best possible manner. More

    Jump to
    • Watch: Hits & Misses of Q3 earnings

      Watch: Hits & Misses of Q3 earnings

      Ushang Sheth joins in for a check on the recent midcap hits & misses.

    • Orchid Chemicals in focus post earnings

      Orchid Chemicals in focus post earnings

      Orchid Chemicals and Pharmaceuticals from the pharmaceutical space has reported good set of numbers on an operational as well as on revenue parameter this quarter on year-on-year, as well as on sequential basis. The stock is likely to be on focus today.

    • Allahabad Bank labels Orchid A/c as NPA, eyes recovery soon

      Allahabad Bank labels Orchid A/c as NPA, eyes recovery soon

      State-owned Allahabad Bank on Tuesday (May 7 2013) announced its fourth quarter earnings. It posted a 68.5 percent decline in net profit at Rs 126.15 crore on account of rise in bad loans. However company‘s non-performing assets (NPAs) have increased by about Rs 1,600 crore.

    • See EBITDA margin at 23-24% in FY14: Orchid Chemicals

      See EBITDA margin at 23-24% in FY14: Orchid Chemicals

      K Raghavendra Rao, chairman and managing director, Orchid Chemicals and Pharmaceuticals is optimistic on the company's performance in the next quarter.

    • Orchid Chemicals eyes 15-20% growth in FY13

      Orchid Chemicals eyes 15-20% growth in FY13

      After not so impressive results and a fall in Q4 net profit by 75%, K Raghavendra Rao, CMD, Orchid Chemicals said that the company‘s topline and bottomline performance has been affected mainly due to the repayment of Foreign Currency Convertible Bonds (FCCB).

    • Orchid Chemicals maintains guidance of 20-25% growth rate

      Orchid Chemicals maintains guidance of 20-25% growth rate

      K Raghavendra Rao, CMD, Orchid Chemicals tells CNBC-TV18 that high interest costs and forex losses impacted the company’s earnings.

    • Can beat FY12 guidance if exchange rate holds: Orchid Chem

      Can beat FY12 guidance if exchange rate holds: Orchid Chem

      Orchid Chemicals reported its second quarter results for FY11. The drug company posted a net profit at Rs. 23.4 crore for the quarter ended September 2011 versus Rs 24 crore in the corresponding period last year.

    • Orchid Chem hopes to maintain EBIDTA margin at 24% in FY12

      Orchid Chem hopes to maintain EBIDTA margin at 24% in FY12

      In an interview with CNBC-TV18, Raghavendra Rao, Orchid Chemicals says, the company is guiding 25% growth in the top-line and more than proportionate growth in bottom-line for FY12. “We should touch about USD 500 million in top-line and more than proportionate growth in bottom-line,” he adds.

    • Expect to better rev guidance by 10%: Orchid Chem

      Expect to better rev guidance by 10%: Orchid Chem

      Speaking to CNBC-TV18, K Raghavendra Rao, MD, Orchid Chemicals expects to end FY11 with margins of 24% and also sees strong double digit growth in the next fiscal i.e. FY12. The company also sees a revision in earlier topline guidance for FY11 and expects an additional 10% growth in revenue this year.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347